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Abstract
Inhibition of tumour necrosis factor (TNF)-alpha with biological
molecules has proven an effective treatment for rheumatoid
arthritis, achieving a 20% improvement in American College of
Rheumatology score in up to 65% of patients. The main
drawback to these and many other biological treatments has
been their expense, which has precluded their widespread
application. Biological molecules could alternatively be
delivered by gene therapy as the encoding DNA. We have
developed novel plasmid vectors termed pGTLMIK and
pGTTMIK, from which luciferase and a dimeric TNF receptor II
(dTNFR) are respectively expressed in a doxycycline (Dox)-
regulated manner. Regulated expression of luciferase from the
self-contained plasmid pGTLMIK was examined in vitro in a
variety of cell lines and in vivo following intramuscular delivery
with electroporation in DBA/1 mice. Dox-regulated expression
of luciferase from pGTLMIK of approximately 1,000-fold was
demonstrated in vitro, and efficient regulation was observed in
vivo. The vector pGTTMIK encoding dTNFR was delivered by
the same route with and without administration of Dox to mice
with collagen-induced arthritis. When pGTTMIK was delivered
after the onset of arthritis, progression of the disease in terms of
both paw thickness and clinical score was inhibited when Dox
was also administered. Vectors with similar regulation
characteristics may be suitable for clinical application.
Introduction
Tumour necrosis factor-alpha (TNF-α) inhibitors, either anti-
bodies to TNF-α (infliximab, adalimumab) or TNF receptors
(TNFRs) fused to an immunoglobulin G-Fc backbone (etaner-
cept), used in combination with methotrexate are the most
effective disease-modifying agents for rheumatoid arthritis
(RA) in terms of improvement in symptoms, quality of life, and
prevention of structural damage. Twenty percent improve-
ments in American College of Rheumatology (ACR) score are
achieved in approximately 65% of patients [1]. However, the
cost of treatment is high (approximately €10,000 per year),
which limits their worldwide use.
The success of anti-TNF-α biologicals in the treatment of RA
provides a well-characterised target to incorporate in a gene
therapy strategy for the treatment of the disease. Due to the
fact that RA is a chronic non-fatal disease, an absolute require-
ment for any gene therapy treatment is that it be completely
safe and ideally have long-term effects. Plasmid DNA, unlike a
virus, is devoid of protein components and is therefore non-
immunogenic. This quality and its inability to integrate into the
genome have established plasmid DNA as a safe gene-deliv-
ery vector. However, the absence of an innate mechanism to
enter cells has also limited the widespread application of plas-
mid DNA in gene therapy. But the ability of plasmid DNA to
efficiently transfect skeletal muscle, originally reported by
Wolff and colleagues [2], has enabled use of plasmid in gene
therapy clinical trials [3,4] and in experimental models. When
combined with electroporation, the transfection efficiency of
skeletal muscle is further enhanced by 100-fold [5], and
reporter gene expression is demonstrated in excess of 250
days. Therefore, plasmid DNA can be delivered efficiently in
ACR = American College of Rheumatology; CIA = collagen-induced arthritis; CII = collagen II; CMV = cytomegalovirus; Dox = doxycycline; dTNFR 
= dimeric tumour necrosis factor receptor II; ECACC = European Collection of Cell Cultures; ELISA = enzyme-linked immunosorbent assay; i.m. = 
intramuscular; i.p. = intraperitoneal; IRES = internal ribosome entry site; LPS = lipopolysaccharide; PBS = phosphate-buffered saline; Ptet = tetra-
cycline-responsive promoter; RA = rheumatoid arthritis; RLU = relative light units; tetR-KRAB = tetracycline repressor-Kruppel-associated box; TNF-
α = tumour necrosis factor-alpha; TNFR = tumour necrosis factor receptor.Arthritis Research & Therapy    Vol 9 No 1    Gould et al.
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vivo, achieving long-term expression, and because it is not
immunogenic can potentially be re-administered.
Despite being a chronic disease, RA can go into periods of
remission [6] and so the use of regulated promoters will ena-
ble the expression of therapeutic molecules to be reduced or
switched 'off' during these phases of the disease. Regulated
expression will also enhance the safety of the system should
adverse effects occur or a second pathology develop. Several
pharmacologically regulated systems of gene expression have
been developed, including the tetracycline system, which uses
the bacterial components of tetracycline resistance in a syn-
thetic system that functions efficiently in eukaryotic cells [7,8].
These original components have been used in a variety of in
vitro systems, in vivo for gene therapy applications, and in
transgenic organisms. They have also been combined in self-
contained vectors that facilitate their application in gene ther-
apy as only a single plasmid needs to be delivered to cells.
Regulated expression with the original tetracycline system is
optimal in stably transfected cells, whereas expression in tran-
siently transfected cells is approximately 50- to 100-fold [9-
11]. The high basal activity of the tetracycline-responsive pro-
moter (Ptet) compromised the function of the system in these
situations. Improved components have since been developed,
including the tetR-KRAB (tetracycline repressor-Kruppel-
associated box), which binds the Ptet and reduces basal activ-
ity in the absence of antibiotic [12]. An improved transactiva-
tor, rtTA2S-M2, was generated that has greater stability than
rtTA (reverse tetracycline transactivator) and is also respon-
sive to a tenth of the concentration of doxycycline (Dox) [13].
These improved components can be used in tandem to give
more efficient gene regulation in vitro and in vivo and have
also been incorporated into self-contained vectors that func-
tion efficiently in vitro and in vivo [14-16].
In this study, we have constructed a self-contained plasmid
vector that incorporates the improved components for tetracy-
cline-regulated gene expression and displays more efficient
gene regulation in a variety of transfected cells when com-
pared to a self-contained vector with the original tetracycline-
regulated components. Efficient regulated gene expression is
also observed in vivo, where the vector is maintained long-
term. When the TNF-α inhibitor dimeric TNF receptor II
(dTNFR) consisting of two extracellular domains of hTNFRII
linked by a flexible serine-glycine linker [17] was encoded from
the vector, efficient regulation is observed in vitro and progres-
sion of arthritis is inhibited in an experimental model.
Materials and methods
DNA and cells
Plasmid DNA was propagated in DH5-α Escherichia coli and
was purified using a standard Plasmid Mega Kit (Qiagen Ltd.,
Crawley, West Sussex, UK); when DNA was prepared for in
vivo application, the EndoFree™ Plasmid Mega Kit (Qiagen
Ltd.) was used. Human skin epithelial cell line A431 (European
Collection of Cell Cultures [ECACC] no. 85090402), mouse
myoblast cell line C2C12 (ECACC no. 91031101), human
embryonic kidney epithelial cell line 293T, mouse DBA/1
embryonic fibroblasts with the temperature-sensitive large T
antigen (DTF) [18], and monke y  k i d n e y  f i b r o b l a s t  C o s 7
(ECACC no. 87021302) were grown at 10% CO2 in Dul-
becco's modified Eagle's medium (BioWhittaker, now part of
Cambrex Bio Science Verviers S.p.r.l., Verviers, Belgium) sup-
plemented with 10% foetal bovine serum (Gibco-BRL, now
part of Invitrogen Corporation, Carlsbad, CA, USA), glutamine
(2 mM) (Cambrex Bio Science Verviers S.p.r.l.), penicillin (100
U/ml) (Cambrex Bio Science Verviers S.p.r.l.), and streptomy-
cin (100 μg/ml) (Cambrex Bio Science Verviers S.p.r.l.).
Unless stated otherwise, reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA).
Plasmid construction
The plasmids pGTL, pGTRTL [11], pGTRTT, pcLuc+ [19],
and pMIK/ZeoSV2 [20] have been described previously. To
facilitate cloning, the sense and anti-sense oligonucleotides of
sequences GATCTTAAGCCATACCCGGGATCGGGATC-
CGACTTGG and TCGACCAAGTCGGATCCCGATCCCG-
GGTATGGCTTAA, respectively, containing restriction sites
for BamHI, SmaI, and AflII, were annealed and cloned into the
plasmid pGL2-Basic (Promega Corporation, Madison, WI,
USA) restricted with BamHI and SalI, producing the plasmid
pGLinker. The MIK cassette containing the improved tetracy-
cline transactivator (rtTA2S-M2) and the repressor tetR-KRAB
from an SV40 promoter along with the upstream zeo gene
were removed from pMIK/ZeoSV2 by restriction with MscI and
AflII and cloned into pGLinker cut with PshA1 and AflII, pro-
ducing the vector pGMIK. The self-contained plasmid
pGTLMIK was then generated by removing Ptet-Luc from
pGTL with XhoI-EcoRV and was cloned into pGMIK restricted
with the same enzymes. Finally, pGTTMIK encoding dTNFR
was constructed by removing Ptet-Luc from pGTLMIK with the
enzymes MluI-EcoNI and by replacing it with Ptet-dTNFR
removed from pGTRTT with the same enzymes. The principal
plasmids used in this study are depicted schematically in Fig-
ure 1.
Cell transfection
Transfections of 293T, A431, DTF, and Cos7 cells were per-
formed using the calcium phosphate precipitation method as
described previously [11]. Cells were plated on 12-well plates
at a density of 0.2 × 106 per well and were transfected the next
day with 2 μg of DNA. Cells were subjected to an osmotic
shock on the second day, after which fresh media was added
with or without Dox at a concentration of 1 μg/ml. Levels of
luciferase in transfected cells were determined in cell lysates,
or dTNFR was measured in supernatants by enzyme-linked
immunosorbent assay (ELISA) (see below).
The myoblast cell line C2C12 was transfected by nucleofec-
tion. These cells were prepared at 1 × 106 per 100 μl andAvailable online http://arthritis-research.com/content/9/1/R7
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were transfected with 2 μg of GTLMIK by means of the amaxa
system (amaxa GmbH, Cologne, Germany) and buffers in kit V
with program B-032. Cells were then plated in 12-well plates,
and fresh medium was added up to 1 ml in each well. Where
necessary, Dox (1 μg/ml) was added to the well and luciferase
activity was determined 24 and 48 hours later.
Luciferase assay
Luciferase activity was determined using the luciferase assay
system (Promega Corporation). Briefly, cells were washed
twice with phosphate-buffered saline (PBS) and were then
lysed with passive lysis buffer at room temperature for 15 min-
utes. Cells were then scraped off plates and transferred to an
Eppendorf tube. For analysis, samples were centrifuged for 5
minutes at 13,000 rpm. A 10-μl aliquot of the sample was
automatically mixed with 50 μl of luciferase assay substrate,
and light emission was measured using an MLX Microtiter®
Plate Luminometer (Dynex Technologies, Chantilly, VA, USA).
Protein concentrations of cell lysates were determined using
the Bradford protein assay (Bio-Rad Laboratories, Inc., Her-
cules, CA, USA), and values of luciferase activity were
expressed as relative light units (RLU) per microgram of
protein.
In vivo plasmid DNA delivery
Mice were treated according to approved Home Office and
institutional guidelines. Naïve or arthritic DBA/1 mice were
given an intraperitoneal (i.p.) injection of the muscle relaxant
Hypnorm™ (Janssen Animal Health, Janssen Pharmaceuticals,
Antwerp, Belgium) and were anaesthetised with halothane
(Concord Pharmaceuticals Ltd, Horsham, West Sussex, UK)
using Boyle's apparatus (British Oxygen Company, now part
of Linde AG, Wiesbaden, Germany). The fur covering the right
quadricep was shaved and the exposed skin was sprayed with
disinfectant. Endotoxin-free plasmid for injection was prepared
in a solution of 0.9% NaCl at a concentration of 500 μg/ml for
reporter gene studies or 833 μg/ml for therapeutic studies.
DNA (20 μl) was administered by intramuscular (i.m.) injection
at three sites, and ultrasound gel (Henleys Medical Supplies
Ltd, Welwyn Garden City, Hertfordshire, UK) was then applied
to the surface of the skin. Caliper electrodes (384L; BTX
Instrument Division, Harvard Apparatus, Holliston, MA, USA)
were applied transversely across the quadriceps, and the mus-
cle was electroporated (four pulses at 200 V/cm, duration 20
ms, frequency 2 Hz) using a BTX Electro Square Porator ECM
830 (Harvard Apparatus). The polarity of the electrodes was
then reversed and the procedure was repeated.
Whole body bioluminescent imaging
In vivo expression of luciferase was monitored by non-invasive
imaging. Mice were given an i.p. injection of 200 μl of luciferin
K+ salt (30 mg/ml; Promega Corporation). After 5 minutes,
animals were anaesthetised by i.p. injection of 50 μl of a 2:1
mixture of Ketaset® (Fort Dodge Animal Health, Southampton,
Hampshire, UK) and Rompun® (Bayer HealthCare, (part of
Bayer Schering Pharma AG) Newbury, Berkshire, UK). Anaes-
thetised mice were then photographed (0.2-second exposure)
and imaged for light emission (10 seconds on medium sensi-
tivity for mice treated with pcLuc+ or 5 minutes on high sensi-
tivity for mice treated with pGTLMIK) with the IVIS® 100 series
(Xenogen Corporation, Hopkinton, MA, USA). Luciferase
images were overlaid on the photograph, and emission of light
was quantified as photons per steradian per square centimetre
using Living Image®  software version 2.5.50.1 (Xenogen
Figure 1
Schematic representation of the vectors used in this study Schematic representation of the vectors used in this study. All vectors are plasmid DNA constructed on the backbone of pGL2-Basic. Promoters are 
either the constitutive SV40 (pSV40) or tetracycline-responsive (Ptet). Encoded transgenes are the reverse tetracycline transactivator (rtTA), the 
improved version (rtTA2S-M2), the tetracycline targeted repressor-Kruppel-associated box (tetR-KRAB), firefly luciferase (Luc), or the dimeric 
tumour necrosis factor receptor II (dTNFR). Other DNA elements are the internal ribosome entry site (IRES) derived from encephalomyocarditis 
virus, the SV40 polyadenylation signal (black triangle), and the spacer sequence of the non-coded zeocin (Zeo) resistance gene.Arthritis Research & Therapy    Vol 9 No 1    Gould et al.
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Corporation) from a defined region of interest around the
quadriceps muscles and from control areas of the same size
on non-injected quadriceps and abdomen of the same mouse.
Induction of collagen-induced arthritis
DBA/1 mice (10 to 12 weeks old) were administered Hyp-
norm™ (0.1 ml, i.p.) and were shaved at the base of the tail.
Bovine collagen II (CII) was emulsified with complete Freund's
adjuvant at a final concentration of 2 mg/ml, and a total of 0.1
ml was injected intradermally at three sites at the base of the
tail. Twenty-one days later, a booster (0.1 ml) consisting of CII
emulsified with incomplete Freund's adjuvant (2 mg/ml) was
injected intradermally across three sites at the tail base. A fur-
ther 5 days later, animals were given an i.p. injection of lipopol-
ysaccharide (LPS) (40 μg in 0.1 ml of PBS) (E. coli Serotype
055:B5; Sigma-Aldrich Company Ltd, Poole, Dorset, UK) to
synchronise disease [21]. The development of arthritis was
monitored every 2 to 3 days and was given a clinical score
based on visual signs of arthritis: 0.25, swelling in a single
digit; 0.5, swelling in more than one digit; 1, swelling and ery-
thema of the paw; 2, swelling of the paw and ankle; 3, com-
plete inflammation of the paw (accordingly, the maximum
score for each mouse was 12). The thickness of hind paws
was measured using POCO 2T calipers (Krœplin Längen-
messtechnik, Schlüchtern, Germany). Mice were monitored
until 40 days after immunisation, at which time they were
terminated.
Two days after injection of LPS (day 28), animals were
assessed for development of arthritis. Animals with a clinical
score of less than 4 were used in gene therapy experiments
and were administered 50 μg of DNA by i.m. injection (60 μl)
at three sites and were electroporated using conditions
described above. Blood was collected by tail bleed prior to
DNA injection, 2 days after injection, and by cardiac puncture
at termination.
Measurement of dTNFR by ELISA
To measure levels of dTNFR, a microtitre plate was coated
with 50 μl of a mouse monoclonal anti-human TNFRII (R&D
Systems, Inc., Minneapolis, MN, USA) at 4 μg/ml overnight at
4°C. Plates were washed with PBS and then blocked with
200 μl of 2% casein solution in PBS for 1 hour at room tem-
perature. Plates were washed with PBS containing 0.05%
Tween 20 (PBS/Tween) prior to incubation of standards (50
μl of human TNFRII [R&D Systems, Inc.] at a concentration of
1 pg/ml to 1 μg/ml diluted in normal mouse serum or complete
media) and samples (50 μl of serum or culture medium) for 3
hours at room temperature. Plates were washed extensively
with PBS/Tween before incubation with 50 μl of biotinylated
goat anti-human TNFRII (R&D Systems, Inc.) at a concentra-
tion of 100 ng/ml for 1 hour at room temperature. Signal was
detected using the TMB microwell substrate system (Kirke-
gaard & Perry Laboratories, Inc., Gaithersburg, MD, USA), the
reaction was stopped by addition of 4 M sulphuric acid (100
μl), and absorbance measurements were performed at 450
nm using an EL 312e microplate biokinetics reader (BioTek
Instruments, Inc., Winooski, VT, USA). The detection limit of
this ELISA was 10 pg/ml.
Measurement of bioactive Dox in sera
Cells (293T) were plated on 96-well plates at 1 × 104 cells per
well. Twenty-four hours later, they were transfected with 50 ng
of GTLMIK plasmid per well using the calcium phosphate pre-
cipitation method but with no osmotic shock. The next day,
medium was replaced with 100 μl of medium containing heat-
inactivated serum samples diluted 1:100. Medium used in this
assay contained Tet system-approved foetal calf serum (Clon-
tech, Mountain View, CA, USA), which is free from trace
amounts of tetracycline or its derivatives. Cells were then lysed
in 50 μl of passive lysis buffer, and luciferase was measured in
accordance with the assay method described above. From
luciferase values obtained for the Dox standard curve (10 pg/
ml to 10 ng/ml), levels of Dox in serum samples were calcu-
lated by multiplying by the dilution factor of 100.
Statistical analysis
Descriptive statistics and significant differences between
groups were calculated using the Student's t tests for two-
sample data of unequal variance (Microsoft® Excel 98 soft-
ware; Microsoft Corporation, Redmond, WA, USA).
Results
Comparison of regulated luciferase expression from 
pGTLMIK and pGTRTL
During the construction of pGTLMIK (Figure 1), the function of
the intermediate vector pGMIK which expressed both rtTA2S-
M2 and tetR-KRAB was confirmed by in vitro co-transfection
experiments (data not shown). Regulated expression of luci-
ferase from pGTLMIK and pGTRTL was compared in a variety
of cell lines. Basal expression from GTLMIK in transfected
DTFs (1.36 ± 0.36 RLU/ng protein) was significantly (p <
0.05) less than basal expression from pGTRTL (55.44 ± 14.5
RLU/ng protein) but was above the non-transfected back-
ground (0.06 ± 0.007 RLU/ng protein). Induction of luciferase
expression from pGTLMIK in DTFs was sensitive to the lowest
Dox concentration (1 pg/ml), whereas GTRTL required a
higher Dox concentration (1 ng/ml) to induce expression
above basal levels. Maximal levels of expression from
pGTLMIK were achieved with 100 ng/ml and 1 μg/ml Dox,
whereas pGTRTL required a concentration of 1 μg/ml for full
induction, and expression levels remained below the maximum
observed with pGTLMIK (Figure 2a). The greater fold induc-
tion of luciferase expression from pGTLMIK compared to
pGTRTL (Figure 2b) was due to the combination of lower
basal and higher induced levels of expression with this vector.
The improved regulated expression of luciferase from
pGTLMIK observed in DTFs was also observed in other cells;
the vector was responsive to lower Dox concentrations,Available online http://arthritis-research.com/content/9/1/R7
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Figure 2
Regulated luciferase expression from self-contained vectors in transfected cells Regulated luciferase expression from self-contained vectors in transfected cells. (a) Comparison of regulated luciferase expression from pGTRTL (2 
μg) (white squares) and pGTLMIK (2 μg) (black squares) in transiently transfected DBA/1 embryonic fibroblasts with the temperature-sensitive large 
T antigen (DTF) cells (2 × 105 cells per well). Cells were grown in doxycycline (Dox)-free or Dox-containing media (concentration range of 1 pg/ml to 
1 μg/ml). After 24 hours, luciferase activity was measured in cell lysates. (b) Fold induction of luciferase expression from pGTRTL (white bars) and 
pGTLMIK in response to Dox was determined in DTF, A431, and 293T transiently transfected cells. Cells were transfected as in (a), and fold induc-
tion was calculated by dividing the Dox-induced value by the non-induced value for each transfection. (c) Regulated expression of luciferase from 
pGTLMIK (1 μg) transfected into the mouse myoblast cell line C2C12 (1 × 106 cells) using the amaxa system. Transfected cells were split between 
the wells of a six-well plate and were either non-induced or induced with Dox (1 μg/ml) for 24 hours. In all panels, luciferase measurements were 
standardised for protein content and each mean value or calculated value was obtained from triplicate transfections. Vertical lines in (a) and (c) rep-
resent standard error of the mean. RLU, relative light units.Arthritis Research & Therapy    Vol 9 No 1    Gould et al.
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displaying lower basal expression and demonstrating higher
induced expression compared with pGTRTL. Regulated
expression of luciferase from GTLMIK was approximately
1,000-fold in mouse fibroblasts (DTF) and human epithelial
cells (A431 and 293T) (Figure 2b).
The intended in vivo application of the regulated plasmid was
transfection of skeletal muscle and so it was important to
examine regulated expression from the vector in the myoblast
cell line C2C12. Again, efficient regulated expression of luci-
ferase was demonstrated 24 and 48 hours after induction with
Dox (1 μg/ml), and the magnitude of induction was approxi-
mately 500-fold at both time points (Figure 2c).
In vivo expression of luciferase detected by non-invasive 
imaging
The vector pcLuc+ encoding the improved luciferase gene
constitutively from a cytomegalovirus (CMV) promoter was
used in vivo to confirm the transfection procedure to muscle
and to determine whether expression levels were maintained
for the duration of the experiment. Expression of luciferase
from this vector, which was detected on day 4, confirmed that
the delivery method was efficient for plasmid DNA (Figure 3a).
In addition, i.m. expression levels of luciferase detected by
imaging were maintained for at least 5 months (Figure 3a),
indicating that plasmid persists long-term in transfected cells
and that the CMV promoter is not silenced and confirming that
luciferase is non-immunogenic in DBA/1 mice.
Figure 3
Constitutive and regulated expression of luciferase in vivo Constitutive and regulated expression of luciferase in vivo. Plasmid DNA (30 μg) pcLuc+ (a) or pGTLMIK (b) was delivered by intramuscular injec-
tion with electroporation on day 0. Mice were imaged using the IVIS system on days 4, 15, 32, 71, and 168 (for the pcLuc+-treated mouse) after 
injection of luciferin substrate and anaesthetisation. Light emission (photons per steradian per square centimetre) was measured from the right leg of 
DNA-injected mice. For pGTLMIK-treated mice, luciferase expression (black bars) is compared with the left leg (white bars) and with a control (C) 
region of the same size on the abdomen (grey bar). Mice received doxycycline (Dox) (200 μg/ml) in sweetened drinking water for 15 days after DNA 
delivery. Dox was then removed until day 67, when the same concentration Dox drink was again supplied. Values for pcLuc+ are obtained from a sin-
gle mouse, and for pGTLMIK the values are the mean from three mice; vertical lines represent the standard error of the mean. Images obtained from 
the three pGTLMIK-injected mice on days 15, 32, and 71 are shown on the right. These results confirm that luciferase expression from pGTLMIK 
can be very efficiently switched on (days 15 and 71) and off (day 32) by addition or removal of Dox from the diet.Available online http://arthritis-research.com/content/9/1/R7
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Regulated expression of luciferase from pGTLMIK in vivo was
also examined by bioluminescence imaging. Three treated
mice were monitored for expression of luciferase following
addition of Dox (200 μg/ml) (days 4, 15, and 71) and removal
of Dox (day 32) from drinking water (Figure 3b). These data
illustrate that the regulated vector operates in vivo, that the tet-
racycline components of regulation are also non-immunogenic
(given that they are expressed long-term), and that the tetracy-
cline promoter Ptet is not inactivated over the 71-day period of
the experiment. Two of these mice were again imaged at 6
months and regulated expression of luciferase was observed
(data not shown). The imaging experiments as a whole also
demonstrate that detectable levels of luciferase are observed
at the site of plasmid injection only and not at distant sites.
Expression of dTNFR from pGTTMIK in Cos 7 cells
Regulated expression of dTNFR from pGTTMIK was examined
in Cos7 cells. Regulated expression with these cells was
approximately 300-fold, and levels of induced expression were
similar to those achieved with the vector pGTRTT in a previous
study [19] (Figure 4a).
Inhibition of collagen-induced arthritis by pGTTMIK
Development of arthritis in the collagen-induced arthritis (CIA)
model was monitored by measurement of paw thickness and
clinical score. In gene therapy experiments, pGTLMIK or
pGTTMIK was administered to mice with early arthritis (clinical
score of less than 4). Groups of mice then received Dox (200
μg/ml) containing sweetened (10% sucrose) water or sweet-
Figure 4
Expression of dimeric tumour necrosis factor receptor II (dTNFR) from pGTTMIK and gene therapy application in the collagen-induced arthritis (CIA)  model Expression of dimeric tumour necrosis factor receptor II (dTNFR) from pGTTMIK and gene therapy application in the collagen-induced arthritis (CIA) 
model. (a) Cos 7 cells were transiently transfected with 2 μg of pGTTMIK by the calcium phosphate method. Expression of dTNFR was induced for 
24 or 48 hours with doxycycline (Dox) (1 μg/ml). Values are the mean of triplicate transfections, and induction values above the black bars allow for 
the endogenous production of TNFR II from non-transfected (NT) cells indicated by the dotted line. (b) Inhibition of CIA in mice treated with 
pGTTMIK and administered Dox. Progression of CIA both in terms of clinical score (I) and hind paw swelling (II) was inhibited by delivery of 
pGTTMIK (50 μg) intramuscularly with electroporation on day 28 after immunisation in mice with early disease (clinical score of less than 4). Inhibi-
tion was evident in those mice that received Dox in sweetened drinking water. Values are the mean, and vertical lines represent the standard error of 
the mean. Significant difference of p < 0.05 and p < 0.02 between the GTTMIK groups given Dox-containing and Dox-free sweetened drinking 
water are indicated by * and **, respectively.Arthritis Research & Therapy    Vol 9 No 1    Gould et al.
Page 8 of 12
(page number not for citation purposes)
ened water alone (GTLMIK without Dox [n = 13], GTLMIK with
Dox [n = 12], GTTMIK without Dox [n = 11], GTTMIK with Dox
[n = 10]). Mice that received pGTTMIK and Dox developed
significantly lower disease in terms of clinical score and hind
paw swelling at days 37 and 40 compared with mice that
received pGTTMIK without Dox (Figure 4b).
Analysis of sera from arthritic mice
Blood samples were collected before and 2 and 13 days after
plasmid DNA (pGTTMIK) administration and were monitored
for levels of Dox and dTNFR. Dox levels were elevated in
serum collected 2 and 13 days after administration of Dox
(Figure 5). Levels were highest after 2 days (20.2 ng/ml) and
were lower (6.7 ng/ml) at the end of the experiment. This
reduction indicates decreased intake of Dox. A reason for this
may be that consumption of Dox-containing water is reduced
with progression of arthritis.
The dTNFR molecule is rapidly removed from the circulation,
unlike the Fc-based TNF-α inhibitors, which have long half-
lives in the serum. The rapid excretion of dTNFR probably
accounts for the low levels of dTNFR in blood of treated mice.
Two days after Dox treatment was initiated, no dTNFR was
detected. At the end of the experiment, detectable levels by
ELISA were determined in the sera of only two mice treated
with pGTTMIK and Dox (Figure 6).
Discussion
Anti-TNF-α is now well established as a biological treatment
for RA and achieves an ACR improvement of 20% in approxi-
mately 65% of patients [22]. More recently, the treatment has
proven effective in other inflammatory diseases, including
Crohn's disease [23] and asthma [24], and may even have
application in cancer treatment [25]. Importantly, the number
of reported side effects remains low, and the greatest concern
is the re-occurrence of tuberculosis in some cases. Although
the effectiveness of these biologics is welcome, their cost still
prohibits their widespread application in the UK and other
European countries and precludes their use in poorer nations.
We believe that the same or similar treatments could be effec-
tively delivered by a safe gene therapy using plasmid vectors
and regulated expression systems.
Plasmids have the advantage that they are non-integrating,
cheap to produce, and can give long-term expression when
delivered to non-dividing cells. Any gene therapy for a chronic
non-fatal disease such as arthritis is required to be safe. Using
a method to regulate expression of the transgene will improve
safety because expression levels can be adjusted to individual
patient needs and if adverse effects occur, expression can be
switched off.
We have previously constructed a self-contained plasmid in an
auto-regulated format which achieved regulated expression in
cells and in vivo after i.m. injection with electroporation
[11,19]. However, regulation was approximately 50-fold, and
basal promoter activity was evident. In this study, we have
used the same plasmid backbone from pGL2-Basic vector,
and an important feature of this vector is the SV40 polyade-
nylation signal, which is bidirectional and can therefore reduce
the vector size by terminating expression of two genes. In the
improved vector format, expression is not auto-regulated,
because the constitutively produced tetR-KRAB actively
represses Ptet activity in the absence of Dox. Repression by
the KRAB domain is achieved by binding of Kap1 and conse-
quent formation of a scaffold to recruit heterochromatin pro-
tein 1, histone deacetylases, and Setdb1, leading to chromatin
condensation [26]. This repression can act over long dis-
tances and has been shown to repress a CMV promoter up to
3 kilobases from the site of KRAB binding [27]. For this rea-
Figure 5
Levels of doxycycline (Dox) in the serum of pGTTMIK-treated mice Levels of doxycycline (Dox) in the serum of pGTTMIK-treated mice. Levels of Dox in the serum from mice that were administered sweetened water 
only (white bars) or Dox (200 μg/ml) (black bars) were determined using pGTLMIK transiently transfected 293T cells. The experiment was per-
formed as decribed in Materials and methods. Dox concentration in the blood was determined from a standard curve of luciferase activity obtained 
with serum spiked with known Dox concentrations. Mean values are shown, and vertical lines represent the standard error of the mean.Available online http://arthritis-research.com/content/9/1/R7
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son, the non-encoding Zeo  gene and downstream
polyadenylation signal (500 base pairs) are included in the
vector as a spacer to increase the distance between the Ptet
and the constitutive SV40 promoter to approximately 3.3 kilo-
bases. In this improved regulated vector, we have incorpo-
rated an internal ribosome entry site (IRES) for co-expression
of rtTA2S-M2 and tetR-KRAB which can result in decreased
expression of the second gene [28]. However, for the purpose
of co-expressing the components for tetracycline-regulated
gene expression, others have also successfully used an IRES
[14,16].
Efficient regulated expression was achieved in a wide variety
of cell lines, including 293T cells in which the tetracycline sys-
tem has previously been shown to function poorly [29]. The
vector also functioned well in the myoblast cell line C2C12,
which is an indicator for activity in vivo when delivered to
skeletal muscle. In all cell lines examined, regulated expression
of luciferase from pGTLMIK was in the range of 500- to 2,000-
fold and expression was regulated more tightly than with
pGTRTL. Regulated luciferase expression from pGTLMIK was
responsive to Dox concentration from 1 pg/ml to 1,000 ng/ml.
The improved gene regulation with pGTLMIK compared to
pGTRTL is due to the active repression of the Ptet by tetR-
KRAB in the absence of Dox; in the presence of low Dox (from
1 pg/ml), this repression is reversed, and at higher Dox con-
centrations (from 100 ng/ml), maximal activation of the Ptet by
rtTA2S-M2 occurs in accordance with the original description
of this activator [13]. An advantage of expressing both tetR-
KRAB and rtTA2S-M2 is that the Ptet is bound in the absence
and presence of Dox and this will limit potential interaction of
endogenous molecules such as GATA factors with the pro-
moter [30].
Intramuscular injection of plasmid DNA combined with electro-
poration is an efficient method to transfect skeletal muscle.
Constitutive expression of luciferase from pcLuc+ from a CMV
promoter was maintained at a consistent level for 5 months,
confirming that luciferase is not immunogenic and that the
CMV promoter is not silenced in this period in vivo. Methyla-
tion of long terminal repeat sequences is well established as a
mechanism for the silencing expression of retroviral integrated
transgene expression [31]. Rapid methylation of the CMV
promoter incorporated in an adenoviral vector was also
reported in vivo following i.m. virus delivery [32]. By contrast,
the results observed in this study support the idea that when
the CMV promoter is incorporated in episomal plasmid DNA,
it is not methylated and remains functional [33]. Regulated
expression of luciferase from pGTLMIK is also maintained 6
months. This indicates that the SV40 promoter driving expres-
sion of the MIK cassette remains active, contrary to a previous
report that its function is transient in skeletal muscle [34]. The
safety of the vector could potentially be further improved by
replacing the ubiquitous SV40 promoter with a muscle-spe-
cific promoter such as the MCK (muscle creatine kinase) pro-
moter [35], which would restrict expression from the plasmid
to transfected skeletal muscle and preclude expression from
plasmid DNA that disseminates from the injection site. Equally,
transfection of potential antigen-presenting cells such as skel-
etal stem cells located within skeletal muscle could lead to
immune rejection of presented transgenes [36]. Again, this
could be circumvented by selectively targeting expression with
a muscle-specific promoter [37].
TNF-α inhibitors are very effective in the treatment of patients
with RA, but in the CIA model TNF-α inhibitors slow the pro-
gression of disease when delivered after disease onset but do
not reverse disease [38,39]. In mice with established CIA, we
show that Dox-induced expression of dTNFR from pGTTMIK
inhibited the progression of disease. This finding is also con-
sistent with our previous observations that both constitutive
expression and Dox-induced expression of dTNFR during the
early stage of CIA inhibit disease development [19]. Similarly,
gene therapy delivering other TNF inhibitors such as a dimeric
TNFRI [40] and TNFRI and TNFRII Fc molecules [40,41]
expressed constitutively from plasmid DNA is also effective in
the treatment of CIA.
The same hurdles for treatment of CIA and RA exist. DNA must
be efficiently delivered, level of gene expression is dependent
on Dox intake, and therapeutic effect requires inhibition of
TNF-α. In mice, delivery of plasmid DNA to skeletal muscle
combined with electroporation is effective, but when the
expressed transgene is not readily detected, transfection can-
not be confirmed. It would be preferable to co-express a
reporter gene whose expression could be used to confirm
muscle transfection. In terms of plasmid delivery in primates,
direct injection into muscle is less efficient than in rodents [42]
and may indicate that alternative delivery methods will be
Figure 6
Levels of dimeric tumour necrosis factor receptor II (dTNFR) in the  circulation Levels of dimeric tumour necrosis factor receptor II (dTNFR) in the cir-
culation. Enzyme-linked immunosorbent assay (ELISA) was used to 
measure dTNFR levels in serum samples collected from mice treated 
with pGTTMIK at the end of the experiment (day 40). Individual samples 
are illustrated for both the doxycycline (Dox)-treated and untreated 
groups. The detection limit for the ELISA was 10 pg/ml.Arthritis Research & Therapy    Vol 9 No 1    Gould et al.
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required for treatment of patients. One potential method is
intravenous hydrodynamic injection, which is equally effective
in rodents and primates and may prove efficient for clinical
application [43].
Administration of Dox (200 μg/ml), a tetracycline analogue in
drinking water, led to levels of bioactive Dox detected in the
blood from day 2 to the end of the experiment. Because Dox
was delivered to a cage and not to individual animals, there
may have been considerable inter-animal variation in the
amount of Dox delivered. Development of arthritis and conse-
quent restriction of movement may also have affected Dox
intake. Interestingly, the levels of bioactive Dox detected in
sera (approximately 10 ng/ml) are considerably lower than
peak blood levels (1 to 2 μg/ml) achieved in patients receiving
100 mg of Dox daily and are also less than 800 ng/ml, which
is the minimal effective anti-microbial concentration [44]. This
substantial difference may be due to poor uptake of Dox deliv-
ered orally in mice. Previous observations with rats and rabbits
have shown that tetracycline delivered in drinking water up to
concentrations of 4,000 μg/ml achieved low (300 ng/ml) or
undetectable tetracycline levels in the sera (limit of assay 200
ng/ml) [45,46]. The low levels of Dox detected in the present
study confirm that the tetracycline system operates well at low
Dox concentrations, and importantly, these Dox levels are sig-
nificantly lower than amounts required for anti-microbial
activity.
In vitro dTNFR is as effective as etanercept-like molecules at
inhibiting TNF-α activity [17] and has previously been shown
to be therapeutic in both the CIA model [19,47] and a multiple
sclerosis model [48]. In the present study, expression of
dTNFR was detected in the blood in only two mice, and in
previous studies dTNFR has been undetected in the blood
[19,48]. It is intriguing how low levels of dTNFR inhibit the pro-
gression of CIA when the dTNFR is not readily detected in the
blood. The dTNFR molecule is excreted in the urine, the same
route as that of endogenous soluble TNFRs [48]. Due to the
rapid half-life of the molecule, it is feasible that TNF-α bound
to dTNFR will be rapidly eliminated by this route. By contrast,
etanercept-like molecules incorporating the immunoglobulin
Fc portion have a long half-life in the blood and bound TNF-α
is retained in the system and not rapidly cleared [49]. When
delivered as protein, a molecule that has a long half-life and
therefore reduces the frequency of re-administration is pre-
ferred; but for gene therapy, in which a molecule is continu-
ously produced, it may be preferable for the molecule to be
rapidly excreted [50].
The investigation reported here builds on our previous
research and demonstrates the improved regulated expres-
sion achieved with a second generation of self-contained vec-
tor. We believe that this type of vector system can be further
developed for clinical application. Plasmid vectors have the
major advantages that they are non-integrating and non-immu-
nogenic and can therefore be re-delivered safely, which is
likely to be a requirement in the treatment of chronic diseases
such as RA. By contrast, all viral vectors contain proteins that
elicit an immune response that complicates or precludes their
re-administration. Before plasmid treatment for chronic dis-
ease can progress to the clinic, efficient delivery is required
and this may be feasible by hydrodynamic injection [43]. For
RA, TNF-α remains an obvious target, but further studies need
to determine the inhibitor with the ideal pharmacokinetic pro-
file for gene therapy application.
Conclusion
Anti-TNF treatment for RA could be delivered safely by gene
therapy through the use of a non-integrating vector and the
use of an efficient gene regulation system. In this paper, we
describe a novel self-contained transcriptionally regulated
plasmid vector encoding a TNF inhibitor which fulfills these
requirements. This gene therapy is effective in mice, but for
application in the clinic, the vector will require additional mod-
ification to improve safety and the components for tetracycline
gene regulation will need to be engineered to prevent
immunogenicity.
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